$Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma$

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma

Moreno, V.; Sepulveda, J.M.; Vieito, M.; HernÃ¡ndez-Guerrero, T.; Doger, B.; Saavedra, O.; Ferrero, O.; Sarmiento, R.; Arias, M.; De Alvaro, J.; Di Martino, J.; Zuraek, M.; Sanchez-PÃ©rez, T.; Aronchik, I.; Filvaroff, E.H.; Lamba, M.; Hanna, B.; Nikolova, Z.; BraÃ±a, I.

期刊名称Annals of Oncology
作者Moreno, V.; Sepulveda, J.M.; Vieito, M.; HernÃ¡ndez-Guerrero, T.; Doger, B.; Saavedra, O.; Ferrero, O.; Sarmiento, R.; Arias, M.; De Alvaro, J.; Di Martino, J.; Zuraek, M.; Sanchez-PÃ©rez, T.; Aronchik, I.; Filvaroff, E.H.; Lamba, M.; Hanna, B.; Nikolova, Z.; BraÃ±a, I.
印刷ISSN0923-7534
文件大小4920.13KB
发表时间2020-3
DOI10.1016/j.annonc.2020.03.294

发现好书期刊，享受阅读乐趣

Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma